Adicet Bio (1IJ) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1IJ Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Adicet

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1IJ Stock 12 Month Forecast

Average Price Target

€17.94

▲(173.83% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Adicet Bio in the last 3 months. The average price target is €17.94 with a high forecast of €21.87 and a low forecast of €15.75. The average price target represents a 173.83% change from the last price of €6.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","13":"€13","22":"€22","8.5":"€8.5","17.5":"€17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.873242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.936058439999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.74873424,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.5,13,17.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.25,8.374864769230769,9.499729538461539,10.624594307692309,11.749459076923078,12.874323846153846,13.999188615384616,15.124053384615387,16.248918153846155,17.373782923076924,18.498647692307692,19.623512461538464,20.748377230769233,{"y":21.873242,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.25,8.072004495384615,8.89400899076923,9.716013486153845,10.53801798153846,11.360022476923074,12.18202697230769,13.004031467692306,13.82603596307692,14.648040458461535,15.47004495384615,16.292049449230767,17.11405394461538,{"y":17.936058439999996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.25,7.903748787692308,8.557497575384616,9.211246363076922,9.86499515076923,10.518743938461538,11.172492726153845,11.826241513846153,12.47999030153846,13.133739089230769,13.787487876923077,14.441236664615383,15.094985452307691,{"y":15.74873424,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.496,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.784,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.184,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.376,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.216,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.268,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€21.87

Average Price Target€17.94

Lowest Price Target€15.75

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€21.87

Buy

233.94%

Upside

Reiterated

05/14/26

Wedbush Sticks to Its Buy Rating for Adicet Bio (ACET)

Boris Peaker

JonesTrading

€17.5

Buy

167.15%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Doximity (NYSE: DOCS)

John Newman

Canaccord Genuity

€15.75

Buy

140.44%

Upside

Reiterated

05/14/26

Canaccord Genuity Remains a Buy on Adicet Bio (ACET)

Anthea Li

Jefferies

Not Ranked

Jefferies

€7→€16.62

Buy

153.80%

Upside

Initiated

05/04/26

Adicet Bio assumed with a Buy at JefferiesAdicet Bio assumed with a Buy at Jefferies

Robert Burns

H.C. Wainwright

€43.75→€23.62

Buy

260.66%

Upside

Reiterated

03/23/26

Adicet Bio: Cash Runway to 2027 and Differentiated Allogeneic Prula‑cel Pipeline Support Buy Rating and $27 Target

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET), Teleflex (NYSE: TFX) and Medacta Group SA (Other OTC: MEDGF)

Yatin Suneja

Guggenheim

€87.49

Buy

1235.77%

Upside

Reiterated

03/13/26

Guggenheim Keeps Their Buy Rating on Adicet Bio (ACET)

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

10/08/25

Adicet Bio (ACET) Receives a Hold from Citizens JMP

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€21.87

Buy

233.94%

Upside

Reiterated

05/14/26

Wedbush Sticks to Its Buy Rating for Adicet Bio (ACET)

Boris Peaker

JonesTrading

€17.5

Buy

167.15%

Upside

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET) and Doximity (NYSE: DOCS)

John Newman

Canaccord Genuity

€15.75

Buy

140.44%

Upside

Reiterated

05/14/26

Canaccord Genuity Remains a Buy on Adicet Bio (ACET)

Anthea Li

Jefferies

Not Ranked

Jefferies

€7→€16.62

Buy

153.80%

Upside

Initiated

05/04/26

Adicet Bio assumed with a Buy at JefferiesAdicet Bio assumed with a Buy at Jefferies

Robert Burns

H.C. Wainwright

€43.75→€23.62

Buy

260.66%

Upside

Reiterated

03/23/26

Adicet Bio: Cash Runway to 2027 and Differentiated Allogeneic Prula‑cel Pipeline Support Buy Rating and $27 Target

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Adicet Bio (NASDAQ: ACET), Teleflex (NYSE: TFX) and Medacta Group SA (Other OTC: MEDGF)

Yatin Suneja

Guggenheim

€87.49

Buy

1235.77%

Upside

Reiterated

03/13/26

Guggenheim Keeps Their Buy Rating on Adicet Bio (ACET)

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

10/08/25

Adicet Bio (ACET) Receives a Hold from Citizens JMP

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adicet Bio

3 Months

John NewmanCanaccord Genuity

Success Rate

7/21 ratings generated profit

Average Return

-4.06%

Copying John Newman's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -4.06% per trade.

1 Year

John NewmanCanaccord Genuity

Success Rate

9/21 ratings generated profit

Average Return

-12.39%

Copying John Newman's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -12.39% per trade.

2 Years

John NewmanCanaccord Genuity

Success Rate

5/21 ratings generated profit

Average Return

-34.90%

Copying John Newman's trades and holding each position for 2 Years would result in 23.81% of your transactions generating a profit, with an average return of -34.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1IJ Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1IJ has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1IJ average Analyst price target in the past 3 months is 17.94.

Each month's total comprises the sum of three months' worth of ratings.

1IJ Financial Forecast

1IJ Earnings Forecast

Next quarter’s earnings estimate for 1IJ is -€1.75 with a range of -€1.92 to -€1.63. The previous quarter’s EPS was -€1.65. 1IJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 1IJ has Performed in-line its overall industry.

1IJ Sales Forecast

Next quarter’s sales forecast for 1IJ is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1IJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 1IJ has Performed in-line its overall industry.

1IJ Stock Forecast FAQ

What is DE:1IJ’s average 12-month price target, according to analysts?

Based on analyst ratings, Adicet Bio Inc’s 12-month average price target is 17.94.

What is DE:1IJ’s upside potential, based on the analysts’ average price target?

Adicet Bio Inc has 173.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Adicet Bio Inc a Buy, Sell or Hold?

Adicet Bio Inc has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Adicet Bio Inc’s share price target?

The average share price target for Adicet Bio Inc is 17.94. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €21.87 ,and the lowest forecast is €15.75. The average share price target represents 173.83% Increase from the current price of €6.55.

What do analysts say about Adicet Bio Inc?

Adicet Bio Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Adicet Bio Inc?

To buy shares of DE:1IJ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Adicet Bio (1IJ) Stock Forecast & Price Target

1IJ Analyst Ratings

1IJ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Adicet Bio

1IJ Analyst Recommendation Trends

1IJ Financial Forecast

1IJ Earnings Forecast

1IJ Sales Forecast

1IJ Stock Forecast FAQ

Detailed List of Analyst Forecasts